Literature DB >> 11187870

The German Registry of immune tolerance treatment in hemophilia--1999 update.

H Lenk1.   

Abstract

As of 1999, the German registry of immune tolerance treatment in hemophilia has received reports on 146 patients who have undergone this therapy from 25 hemophilia centers. In 16 of the reported patients treatment is ongoing. Therapy has been completed in 126 patients of all groups with hemophilia A; most of them are children. In 78.6% of hemophilia A patients full success was achieved, 8.7% finished with partial success, and in 12.7% ITT failed. Statistical analysis demonstrates that interruptions of therapy have a negative influence on success. The inhibitor titer has the highest predictive value for success or failure of therapy. A high maximum titer as well as a high titer at start of treatment were related to a low success rate. Other variables such as exposure days and time interval between inhibitor detection and start of ITT were not statistically significant. Four patients with hemophilia B have also completed therapy, only one of them with success.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11187870

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  20 in total

Review 1.  Key issues in inhibitor management in patients with haemophilia.

Authors:  Keith Gomez; Robert Klamroth; Johnny Mahlangu; Maria E Mancuso; María E Mingot; Margareth Castro Ozelo
Journal:  Blood Transfus       Date:  2013-12-03       Impact factor: 3.443

Review 2.  Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

3.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

4.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 5.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

6.  Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.

Authors:  Yuto Nakajima; Hitoshi Tonegawa; Mariko Noguchi-Sasaki; Keiji Nogami
Journal:  Int J Hematol       Date:  2021-02-26       Impact factor: 2.490

7.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 8.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 9.  Management of factor VIII inhibitors.

Authors:  Donna M Dimichele
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

10.  Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.

Authors:  C Leissinger; C D Josephson; S Granger; B A Konkle; R Kruse-Jarres; M V Ragni; J M Journeycake; L Valentino; N S Key; J C Gill; K R McCrae; E J Neufeld; C Manno; L Raffini; K Saxena; M Torres; V Marder; C M Bennett; S F Assmann
Journal:  Thromb Haemost       Date:  2014-06-12       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.